Ophthalmology 360
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Photo Contest
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
2nd Annual Photo Contest - Enter Here!
Ophthalmology 360
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Photo Contest
    • Industry Council
    • Advisory Board
Home > Oculoplastics > Choroidal thickening may be an indicator of disease activity in thyroid eye disease
  • Oculoplastics

Choroidal thickening may be an indicator of disease activity in thyroid eye disease

Ophthalmology 360

Using swept-source optical coherence tomography (SS-OCT) revealed that subfoveal choroidal thickness (SFCT) is significantly thicker in patients with active thyroid-associated ophthalmopathy (TAO) compared to those with inactive disease and healthy controls, according to a study. In addition, the research highlights the strong correlation between SFCT and the Clinical Activity Score in TAO patients.

The study included 30 patients (60 eyes) with TAO and 38 controls (67 eyes).

Patients with active disease had a thicker mean SFCT (276.23±84.01 µm) in comparison to those with inactive disease (224.68±111.61 µm; P = 0.049) and the healthy control cohort (223.56±78.69 µm; P = 0.01). However, no significant distinctions in SFCT were observed between patients with moderate-to-severe disease, those with severe disease, and the healthy control group (P > 0.05). Additionally, alterations in SFCT demonstrated a robust predictive capacity in discerning active TAO from its inactive counterpart (area under the curve=0.659, 95% CI 0.496 to 0.822).

Reference
Zhong S, He F, Fang S, et al. Choroidal thickness in patients with thyroid-associated ophthalmopathy, as determined by swept-source optical coherence tomography. Br J Ophthalmol. 2023 Oct 19:bjo-2023-323694. doi: 10.1136/bjo-2023-323694. Epub ahead of print. PMID: 37857455.

Share

Related Content

  • Oculoplastics

Pain measures may help track treatment response in Graves’ orbitopathy

FDA approves Eysuvis for short-term treatment of dry eye disease
  • Oculoplastics

FDA approves Lumvoa for active and chronic thyroid eye disease

Cornea Update: Corneal Dystrophies & Related Conditions with an Update on Genetic Assessment and Treatment
  • Cornea and External Disease

Preventing complications of superficial keratectomy

  • Oculoplastics

Blepharoplasty candidates prioritize function over aesthetics, survey finds

  • Oculoplastics

Integrating amniotic allografts into modern oculoplastic reconstruction: a practical perspective

  • The Ophthalmic Project

The next generation of amniotic membranes for the treatment of corneal epithelial defects

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Ophthalmology 360

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon